Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Concordance between circulating tumor DNA and tissue biopsy in patients with newly diagnosed recurrent breast cancer.

Ana Elisa Lohmann, Marguerite Ennis, Zachary William Neil Veitch et al. Jun 01, 2026 pp. 1031-1031 10.1200/jco.2026.44.16_suppl.1031

1031 Background: Accurate determination of tumor origin and molecular subtype are recommended for patients with suspected...

Lost in the referral loop: Improving completion of cancer genetics referrals through targeted patient outreach.

Nitisha Ponnappan, Lauren Mitchell, Tina Karimaghaie et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23298

e23298 Background: As awareness of the clinical value of cancer genetic testing increases, combined with reduced costs and...

Quality of death according to the peaceful end-of-life theory in a hospice in southern Brazil.

Giulia Tulio Baranhuk, Luiz Sérgio Alves Batista II, Rosimeire Batista Pereira et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24048

e24048 Background: The peaceful end-of-life theory is grounded in five central concepts: absence of pain, a state of peace...

CAMPERR: A multicenter, prospective, observational study to evaluate a cfDNA-based genome-wide methylation enrichment assay for multicancer early detection (MCED), identification of molecular residual disease, and relapse prognostication.

Gregory Idos, Faith L. Holmes, Lisa A. Boardman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps10628

TPS10628 Background: Despite advances in cancer treatment, a lack of established population-level cancer screening strateg...

Association between palliative care consultation and end-of-life care intensity in multiple myeloma.

Muhammad Haseeb Khan, Rabbia Irfan, Nimra Niaz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24062

e24062 Background: Multiple myeloma (MM) is characterized by an unpredictable disease course, repeated lines of therapy, a...

Neoadjuvant HPV16-specific viral immunotherapy (HB200) plus chemotherapy with response-adapted de-escalation in HPV16+ oropharyngeal squamous cell carcinoma: TARGET-HPV trial.

Ari Joseph Rosenberg, Aditya Juloori, John Cursio et al. Jun 01, 2026 pp. 6097-6097 10.1200/jco.2026.44.16_suppl.6097

6097 Background: Neoadjuvant immunotherapy is an emerging strategy in head and neck squamous cell carcinoma to enhance sys...

Cost impact of GA-informed re-evaluation of multidisciplinary tumor board plans in thoracic oncology.

Alicia Castelo-Loureiro, Myriam Rodriguez-Couso, Natalia Barreras et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23156

e23156 Background: Standard thoracic oncology regimens in older adults may not reflect multidomain geriatric vulnerabiliti...

Chemotherapy as a shaper of immune communication in the triple-negative breast cancer microenvironment.

David Otohinoyi, Sravya Sri Kuchipudi, Archa Rajesh et al. Jun 01, 2026 pp. 3093-3093 10.1200/jco.2026.44.16_suppl.3093

3093 Background: Triple-negative breast cancer (TNBC) is a highly immunogenic disease and exhibits among the highest level...

Association of high postoperative physical activity with ctDNA MRD positivity and recurrence-free survival across solid tumors: The SCRUM-MONSTAR LIFELOG study.

Shugo Yajima, Shin Kobayashi, Tadayoshi Hashimoto et al. Jun 01, 2026 pp. 10540-10540 10.1200/jco.2026.44.16_suppl.10540

10540 Background: Physical activity is associated with improved survival across multiple cancer types, yet its relationshi...

Real-world management strategies and outcomes of brain metastases in patients with mRCC.

Faisal Abdullah Alsadoun, Lori Wood, Aly-Khan A. Lalani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16531

e16531 Background: Brain metastases (BM) occur in 10–20% of patients (pt) with metastatic renal cell carcinoma (mRCC) and...

A pilot study of a digital, patient-directed consent process for MSK-IMPACT tumor-normal genetic testing in gynecologic cancer.

Varshini Gali, Yue Liu, Nancy Varice et al. Jun 01, 2026 pp. 10604-10604 10.1200/jco.2026.44.16_suppl.10604

10604 Background: Although germline and somatic genetic testing is increasingly recommended for many cancers including gyn...

National trends and disparities in early-onset non-colorectal cancer mortality in the United States, 1999–2023: A population-based analysis of 240,190 deaths.

Kumail Mustafa Ali, Shree Rath, Muhammad Ali et al. Jun 01, 2026 pp. 12106-12106 10.1200/jco.2026.44.16_suppl.12106

12106 Background: Early-onset non-colorectal malignancies account for a substantial share of premature cancer mortality in...

Molecular stratification and actionable genomic alterations in endometrial carcinoma: Real world data from an Indian tertiary oncology centre.

Jeyhan Dhabhar, Dr. Bhardwaj Neelesh, Dr. Boman N. Dhabhar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15174

e15174 Background: Endometrial cancer (EC) is the sixth most common malignancy among women worldwide, with over 420,000 ne...

Unsupervised clustering of RNA-Seq data to identify molecular subtypes of sarcomas.

Michael J. Robinson, Emma A. Schremp, Timothy Su et al. Jun 01, 2026 pp. 11547-11547 10.1200/jco.2026.44.16_suppl.11547

11547 Background: Sarcomas are a rare and heterogeneous group of malignancies, which include over 100 histological subtype...

Association of inpatient outcomes and resource utilization with an ICD-10–defined immune-related adverse event phenotype during U.S. cancer hospitalizations: National Inpatient Sample, 2018–2022.

Fiza Farrukh, Tarek Tabbah, Daniel Thomas Jones et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23104

e23104 Background: Immune checkpoint inhibitor use is rapidly expanding, yet immune-related adverse events (irAEs) are not...

A phase Ib/II trial of first-line trastuzumab, nivolumab, gemcitabine, and cisplatin in HER2-positive biliary tract cancer (HERBOT): A multi-institutional study from the Korean Cancer Study Group.

Choong-kun Lee, Taek Chung, Il Hwan Kim et al. Jun 01, 2026 pp. 4016-4016 10.1200/jco.2026.44.16_suppl.4016

4016 Background: Several phase II trials support HER2 as a promising actionable target in advanced biliary tract cancers (...

Using large language models to identify advance care planning in oncology patients who present to the emergency department.

Nicole Agaronnik, Thomas Sounack, Kei Ouchi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13642

e13642 Background: Large language models (LLMs) can identify advance care planning (ACP) in unstructured notes in a fracti...

Retrospective evaluation of romiplostim use for patients with chemotherapy-induced thrombocytopenia.

Nirja Shah, Nidhi Kanchan, Michael Y. Choi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24161

e24161 Background: Chemotherapy-induced thrombocytopenia (CIT) is a frequent complication, resulting in increased bleeding...

Cumulative incidence and risk factors of trastuzumab deruxtecan–related interstitial lung disease in a multicenter real-world cohort.

Carla Gullotta, Roberta Scafetta, Giovanna Garufi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15030

e15030 Background: Interstitial lung disease (ILD) is a clinically relevant adverse event associated with trastuzumab-deru...

Trends and disparities in sepsis-related mortality among patients with lung cancer: A 25-year nationwide analysis.

Pranav Vempati, Bhaskar Kambhampati, Bhanuprakash Reddy Bathula et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20682

e20682 Background: Lung cancer patients face heightened sepsis susceptibility due to disease-related immune dysfunction an...

Impact of modern systemic and multimodality treatments on post-relapse survival in retroperitoneal soft-tissue sarcoma: A digital-twin target trial emulation study.

Roberta Sanfilippo, Andrea Franza, Gabriele Tinè et al. Jun 01, 2026 pp. 11576-11576 10.1200/jco.2026.44.16_suppl.11576

11576 Background: We previously observed a significant improvement in post-relapse overall survival (OS) in patients with...

The overlapping burden of atrial fibrillation and lung cancer: Insights from U.S. mortality data from 1999 to 2023.

Chanchal Maheshwari, Eshal Amir, Aijaz Zeeshan Khan Chachar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20672

e20672 Background: Both lung cancer and atrial fibrillation (AF) are significant causes of morbidity and death in the US,...

CLARITY-GBM: A phase II, multi-centered, open-label, single-arm study to evaluate the safety and efficacy of cetuximab and lomustine (CCNU) in adult patients with recurrent high-grade glioblastoma.

Zoya Peelay, Kritika Mehrotra, Atanu Bhattacharjee et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2095

TPS2095 Background: Recurrent glioblastoma (GBM) has a poor prognosis with no universally accepted systemic standard of ca...

Transarterial embolization plus hepatic arterial infusion chemotherapy combined with rivoceranib and camrelizumab for initially unresectable hepatocellular carcinoma with high tumor burden: A single-arm, prospective, multicenter study.

Yiping Chen, Zhongwu Chen, Fuqun Wei et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16156

e16156 Background: In recent years, combination treatment strategies incorporating transarterial locoregional therapies wi...

Temporal trends and racial disparities in anal squamous cell carcinoma outcomes: A population-based study.

Bryan Michael Greenfield, Joseph Antony Elengickal, Darren E. Mullins Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15504

e15504 Background: Anal squamous cell carcinoma (SCC) is a relatively uncommon malignancy, accounting for approximately 2%...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page